In patients previously treated with luspatercept, 33% achieved 1-year TI
"New efficacy data related to the 16% (6/38) of patients in IMerge Phase 2 who were relapsed/refractory to ESAs and had also been treated previously with luspatercept are as follows:
50% (3/6) of these patients achieved ≥8-week TI
67% (2/3) of those ≥8-week TI responders also achieved ≥24-week TI
100% (2/2) of those ≥24-week TI responders also achieved >1 year TI"
https://ir.geron.com/investors/press-re ... fault.aspx
ASH PR highlights TI patients previously treated with Luspatercept
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam